Business as usual at PolyMedica.

Yesterday PolyMedica Corporation (NASDAQ: PLMD, $26.62) announced that Stephen C. Farrell was named President of Liberty Healthcare Group to replace W. Keith Trowbridge who resigned effective immediately. Prior to his employment at PolyMedica, Mr. Trowbridge was an officer of Transworld Healthcare, Inc., T2 Medical and Medical Associates of America. Transworld and T2 each faced Medicare fraud allegations and Medical Associates declared bankruptcy after Mr. Trowbridge left. During the five years that Mr. Trowbridge was employed by PolyMedica, quarterly sales grew from $30.6 million to $105.2 million and quarterly EBITDA grew from $4.8 million to $23.4 million. Clearly a lack of generating revenue growth and earnings growth were not the reasons for Mr. Trowbridge’s departure. Our belief is that Mr. Trowbridge’s departure is merely the latest shallow attempt by PolyMedica to appease government prosecutors. We see no reason whatsoever to believe that this latest management change can in any way reduce the magnitude of PolyMedica’s incurred liabilities that result from its alleged criminal conduct. We simply see no ability for PolyMedica to operate profitably without abusing the Medicare system and its beneficiaries.

All of Asensio & Company, Inc.’s reports are covered by the terms and conditions of the mandatory user agreement located at /?page_id=25. The statements below are a part of the user agreement whose entirety is incorporated herein by reference. These statements, and all of the statements contained in the mandatory user agreement, are intended to strictly limit our potential liability to you and your possible legal rights to the fullest extent of the law. Readers are advised to carefully read the entirety of the mandatory user agreement and strictly adhere to the directions given therein.

INVESTMENTS IN SECURITIES, COMMODITIES OR FUTURES HAVE INHERENT RISK, AND A PERSON TAKES SUCH RISKS KNOWINGLY AND BEARS FULL RESPONSIBILITY FOR HIS/HER OWN INVESTMENT RESEARCH AND DECISIONS. Use of this site is at your own risk. None of the information contained herein should be construed as an offer to sell or a solicitation of an offer to buy any securities. In cases where there exists controversy concerning a company’s disclosures, investors should not sell or buy their shares based on the theory that markets price securities efficiently. Furthermore, investors should not rely on the market to substitute for their own individual due diligence and deliberate decision making.

All of the information provided by Asensio & Company, Inc. at must be taken as a whole and in its entirety. All of the statements on involve, concern and are directed at public issues and public controversies of interest to the public at large. contains no statements of fact. All of the statements published by constitute written opinions and are not provided to assist any individual or entity in making any investment decision.